







IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of)	
Kok-Hwee Ng, et al.)	Attorney Docket No. 1417P P594
Serial No.: 09/865,052)	
Filed: May 24, 2001)	
For: A System and Method for)	
Converting an Existing Blood)	
Collection Instruments)	
Communication Protocol)	

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 CFR § 1.97, Applicants submit herewith Form PTO-1449 and attached cited references.

The Examiner is requested to consider carefully the complete text of the enclosed references in connection with the examination of this application. It is believed that the Examiner will concur with Applicants that the subject matter claimed in the present application is neither anticipated nor rendered obvious by these references.

It is requested that the listed references be made of record and included in the "References Cited" portion of any patent issuing from this application.

This art is being submitted before receipt of the first Official Action, therefore, no fee is required.

You are hereby authorized to debit our Deposit Account No. 23-0280 for

any payment deficiencies with regard to this matter.

Respectfully submitted,

Date: August 22, 2001

Peter M. Klobuchar, Reg. No. 43,722 WALLENSTEIN & WAGNER, LTD. 311 South Wacker Dr., 53rd Floor Chicago, IL 60606 (312)554-3300

129038


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, postage prepaid, addressed to:

Commissioner for Patents Washington, D.C. 20231

on August 22, 2001

Merianne M. Flannery

Gerianne M. Flannery



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of) .	•
Kok-Hwee Ng, et al.)	Attorney Docket No. 1417P P594
Serial No.: 09/865,052)	٠
Filed: May 24, 2001)	
For: A System and Method for)	
Converting an Existing Blood)	
Collection Instruments)	
Communication Protocol)	

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 CFR § 1.97, Applicants submit herewith Form PTO-1449 and attached cited references.

The Examiner is requested to consider carefully the complete text of the enclosed references in connection with the examination of this application. It is believed that the Examiner will concur with Applicants that the subject matter claimed in the present application is neither anticipated nor rendered obvious by these references.

It is requested that the listed references be made of record and included in the "References Cited" portion of any patent issuing from this application.

This art is being submitted before receipt of the first Official Action, therefore, no fee is required.

You are hereby authorized to debit our Deposit Account No. 23-0280 for

any payment deficiencies with regard to this matter.

Respectfully submitted,

Date: August 22, 2001

Peter M. Klobuchar, Reg. No. 43,722 WALLENSTEIN & WAGNER, LTD. 311 South Wacker Dr., 53rd Floor

Chicago, IL 60606 (312)554-3300

129038

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, postage prepaid, addressed to:

Commissioner for Patents Washington, D.C. 20231

on August 22, 2001

Gerianne M. Flannery

OIPE 400

#5

TATE OR MATION DISCLOSURE STATEMENT BY APPLICANT

PTO-1449

WW&H File No.: 1417 P P 594 Applicant: Kok-Hwee Ng, et al.

Serial No.: 09/865,052 Filing Date: May 24, 2001

U.S. PATENT DOCUMENTS

-	0.5.171121	1 DOCUMENTS	
Examiner Initial	Document Number	Date	Inventor Name
	H1347	08/02/1994	Greeninger et al.
	3,809,871	05/07/1974	Howard et al.
	3,810,102	05/07/1974	Parks, III et al.
	4,151,407	04/24/1979	McBride et al?
	4,308,866	.01/05/1982	Jelliffe et al.
	4,490,798	12/25/1984	Franks et al.
	4,529,401	07/16/1985	Leslie et alg
	4,561,443	12/31/1985	Hogrefe et al.
	4,624,661	11/25/1986	Arimond
	4,681,563	07/21/1987	Deckert et al.
	4,695,955	09/22/1987	Faisandier #
	4,722,734	02/02/1988	Kolln
	4,741,732	05/03/1988	Crankshaw et al.
	4,754,401	06/28/1988	Kaczynski et al. 7
	4,756,706	07/12/1988	Kerns et al.∮
	4,832,033	05/23/1989	Maher et al.
	4,838,275	06/13/1989	Lee
	4,889,132	12/26/1989	Hutcheson et al.
	4,943,279	07/24/1990	Samiotes et jal.
	4,978,335	12/18/1990	Arthur, III
	5,012,411	04/30/1991	Policastro et al.

AUG 2 4 2007 B		•	
THAUEHART S	5,025,374	06/18/1991	Roizen et al.
MADEM	5,034,004	07/23/1991	Crankshaw
-	5,038,800	08/13/1991	Oba [†]
	5,053,990	10/01/1991	Kreifels et al. ₹
	5,078,683	01/07/1992	Sancoff et al.
	5,100,380	03/31/1992	Epstein et al.
	5,131,816	07/21/1992	Brown et al.
	5,153,827	10/06/1992	Coutré et al.
	5,176,004	01/05/1993	Gaudet ,
	5,181,910	01/26/1993	Scanlon ;
	5,228,450	07/20/1993	Sellers /
	5,231,990	08/03/1993	Gauglitz
	5,238,001	08/24/1993	Gallant et al. 7
	5,256,157	10/26/1993	Samiotes et al. 7
	5,265,431	11/30/1993	Gaudet et al. 7
	5,317,506	05/31/1994	Coutré et al
	5,331,549	07/19/1994	Crawford, Jr.
***	5,336,245	08/09/1994	Adams Theodore P. et al!
	5,337,230	08/09/1994	Baumgartner et al.
	5,338,157	08/16/1994	Blomquist,
	5,341,291	08/23/1994	Roizen et al.
	5,348,008	09/20/1994	Bornn et al.
	5,366,896	11/22/1994	Margrey et al!
	5,374,965	12/20/1994	Kanno f
	5,375,604	12/27/1994	Kelly et al.
	5,376,070	12/27/1994	Purvis et al. /

OIPE AUG 2 1 2000

5;378;231 01/03/1995 Johnson et ăl. 5,392,209 02/21/1995 Eason et al. 5,395,320 03/07/1995 Padda et al. 5,421,343 06/06/1995 Feng 5,438,607 08/01/1995 Przygoda, Jr. et al. 5,445,621 08/29/1995 Poli et al. 5,445,621 08/29/1995 Unger 5,471,382 11/28/95 Tallman et al. 5,485,408 01/16/1996 Blömquist 5,496,265 03/05/1996 Eangley/et-al. 5,531,697 07/02/1996 Olsen et al. 5,542,420 8/6/96 Goldman et al. 5,549,117 08/27/1996 Facklind,et al. 5,558,638 09/24/1996 Evers et al. 7,562,621 10/08/1996 Claude et al. 6,562,621 10/08/1996 Claude et al.
5,392,209 02/21/1995 Eason et al. 5,395,320 03/07/1995 Padda et al. 5,421,343 06/06/1995 Feng 5,438,607 08/01/1995 Przygoda, Jr. et al. 5,445,621 08/29/1995 Poli et al., 5,458,123 10/17/1995 Unger 5,485,408 01/16/1996 Blömquist 5,496,265 03/05/1996 Eangley,et al. 5,531,697 07/02/1996 Olsen et al. 5,542,420 8/6/96 Goldman et al. 5,547,470 08/20/1996 Johnson et al. 5,558,638 09/24/1996 Evers et al. 5,562,621 10/08/1996 Claude et al.
5,421,343 06/06/1995 Feng 5,438,607 08/01/1995 Przygoda, Jr. et al. 5,445,621 08/29/1995 Poli et al.; 5,458,123 10/17/1995 Unger 5,471,382 11/28/95 Tallman et al.; 5,485,408 01/16/1996 Blomquist 5,496,265 03/05/1996 Langley, et al.; 5,531,697 07/02/1996 Olsen et al.; 5,542,420 8/6/96 Goldman et al.; 5,547,470 08/20/1996 Johnson et al.; 5,549,117 08/27/1996 Tacklind, et al.; 5,558,638 09/24/1996 Evers et al 5,562,621 10/08/1996 Claude et al.
5,438,607 08/01/1995 Przygoda, Jr. et al. 5,445,621 08/29/1995 Poli et al.; 5,458,123 10/17/1995 Unger 5,471,382 11/28/95 Tallman et al.; 5,485,408 01/16/1996 Blomquist 5,496,265 03/05/1996 Langleyzet al.; 25,531,697 07/02/1996 Olsen et al.; 5,542,420 8/6/96 Goldman et al.; 5,547,470 08/20/1996 Johnson et al.; 5,549,117 08/27/1996 Tacklind et al.; 5,558,638 09/24/1996 Evers et al.; 5,562,621 10/08/1996 Claude et al.;
5,445,621 08/29/1995 Poli et al., 5,458,123 10/17/1995 Unger 5,471,382 11/28/95 Tallman et al., 5,485,408 01/16/1996 Blomquist 5,496,265 03/05/1996 Langleyretial. 5,531,697 07/02/1996 Olsen et al., 5,531,698 07/02/1996 Olsen 5,542,420 8/6/96 Goldman et al., 5,547,470 08/20/1996 Johnson et al., 5,549,117 08/27/1996 Facklind,et al., 5,558,638 09/24/1996 Evers et al., 5,562,621 10/08/1996 Claude et al.,
5,458,123 10/17/1995 Unger 5,471,382 11/28/95 Tallman et al. 5,485,408 01/16/1996 Blomquist 5,496,265 03/05/1996 Eangleyzet al. 25,531,697 07/02/1996 Olsen et al. 5,531,698 07/02/1996 Olsen 5,542,420 8/6/96 Goldman et al. 5,547,470 08/20/1996 Johnson et al. 5,549,117 08/27/1996 Tacklind,et al. 5,558,638 09/24/1996 Evers et al. 3,562,621 10/08/1996 Claude et al.
5,471,382 11/28/95 Tallman et al. 5,485,408 01/16/1996 Blömquist 5,496,265 03/05/1996 Langleyetal. 25,531,697 07/02/1996 Olsen et al. 5,531,698 07/02/1996 Olsen. 5,542,420 8/6/96 Goldman et al. 5,547,470 08/20/1996 Johnson et al. 5,549,117 08/27/1996 Tacklind,et al. 5,558,638 09/24/1996 Evers et al. 5,562,621 10/08/1996 Claude et al.
5,485,408 01/16/1996 Blomquist 5,496,265 03/05/1996 Langley et al. 25,531,697 07/02/1996 Olsen et al. 5,531,698 07/02/1996 Olsen 5,542,420 8/6/96 Goldman et al. 5,547,470 08/20/1996 Johnson et al. 5,549,117 08/27/1996 Tacklind,et al. 5,558,638 09/24/1996 Evers et al. 5,562,621 10/08/1996 Claude et al.
5,496,265 03/05/1996 Langley-et-al. 25,531,697 07/02/1996 Olsen et al. 5,531,698 07/02/1996 Olsen 5,542,420 8/6/96 Goldman et al. 5,547,470 08/20/1996 Johnson et al. 5,549,117 08/27/1996 Facklind-et al. 5,558,638 09/24/1996 Evers-et-al. 5,562,621 10/08/1996 Claude et al.
55,531,697 07/02/1996 Olsen et al. 5,531,698 07/02/1996 Olsen 5,542,420 8/6/96 Goldman et al. 5,547,470 08/20/1996 Johnson et al. 5,549,117 08/27/1996 Tacklind, et al. 5,558,638 09/24/1996 Evers et al. 5,562,621 10/08/1996 Claude et al.
5,531,698 07/02/1996 Olsen 5,542,420 8/6/96 Goldman et al. 5,547,470 08/20/1996 Johnson et al. 5,549,117 08/27/1996 Tacklind,et al. 5,558,638 09/24/1996 Evers et al. 5,562,621 10/08/1996 Claude et al.
5,542,420 8/6/96 Goldman et al. 5,547,470 08/20/1996 Johnson et al. 5,549,117 08/27/1996 Tacklind et al. 5,558,638 09/24/1996 Evers et al. 5,562,621 10/08/1996 Claude et al.
5,547,470 08/20/1996 Johnson et al 5,549,117 08/27/1996 Tacklind et al 5,558,638 09/24/1996 Evers et al 5,562,621 10/08/1996 Claude et al
5,549,117 08/27/1996 —Tacklind_et_al 5,558,638 09/24/1996 Evers et-al 10/08/1996 Claude et al. \(\)
5,558,638 09/24/1996 Evers-et-al 5,562,621 10/08/1996 Claude et al.
5,562,621 10/08/1996 Claude et al.
5,573,506 11/12/1996 Vasko
5,579,378 11/26/1996 Arlinghaus, Jr?
5,581,687 12/03/1996 Lyle et al.
5,586,171 12/17/96 McAllister et al.
5,590,648 01/07/1997 Mitchell et al. 3
5,597,995 1/28/97 Williams et al.
5,619,991 O4/15/1997 Sloane
5,623,925 - 04/29/1997 Swenson et al.
5,633,910 05/27/1997 Cohen

OIPE			•
AUG 2 L 2001			
TRADEMAR	5;640;953	06/24/1997	Bishop et al.
	5,643,212	07/01/1997	Coutré et al.
	5,647,854	07/15/1997	Olsen et al.
	5,651,775	07/29/1997	Walker et al:
	5,658,240	08/19/1997	Urdahl et al.
	5,658,250	08/19/1997	Blomquist et al-
, , , , , ,	5,664,270	09/09/1997	Bell et al
	5,666,400	09/09/1997	McAllister et al.
	5,669,877	09/23/1997	Blomquist
	5,678,562	10/21/1997	Sellers
	5,681,285	10/28/1997	Ford et al.
	5,683,367	11/04/1997	Jordan et al.
	5,687,717_	11/18/97	Halpern et al:
	5,687,734	11/18/1997 -	Dempsey et al.
	5,697,899	12/16/1997	Hillman et al.
	5,701,894	12/30/1997	Cherry et al.
	5,712,798	01/27/1998	Langley et al.
	5,712,912	01/27/98	Tomko et al.
	5,713,485	2/3/98	Liff et al.
	5,713,856	02/03/1998	Eggers et al.
	5,715,823	02/10/1998	Wood et al.
	5,719,761	02/17/1998	Gatti et al.
	5,722,947	_06/30/1998	Hull et al.
	5,724,025	03/03/1998	Tavori
	5,735,887	04/07/1998	Barreras, Sr. et al.
	5,737,539	4/7/98	Edelson et al.

AUG 2 L ZOM . W

(*	5,738,102	04/14/1998	Lemelson
	5,752,976	05/19/1998	Duffin et al.
	5,772,586	6/30/98	Heinonen et al.
1.	5,772,635	06/30/1998	Dastur et al.
	5,776,057	07/07/1998	Swenson et al.
	5,778,882	07/14/1998	Raymond et al.
	<i>(</i> 5,795,327	08/18/1998	Wilson et àl?
	5,807,336	09/15/1998	Russo et al.
	-5,810,747	09/22/1998	-Brudny et al:
	5,813,972	09/29/1998	Nazarian et al.
	5,814,015	09/29/1998	Gargano et al.
	5,822,544	10/13/98	Chaco et al.
	5,829,438	11/03/1998	Gibbs et al.
	5,841,975	11/24/1998	Layne et al.
	5,842,976	12/01/1998	Williamson
	5,851,186	12/22/1998	Wood et al.
	5,855,550	1/5/99	Lai et al.
	5,857,967	01/12/1999	Frid et al.
	5,859,972	01/12/1999	Subramaniam et al.
	5,865,745	2/2/99	Schmitt et al.
	5,867,821	02/02/1999	Ballantyne et al.
	5,871,465	02/16/1999	Vasko
	5,876,926	03/02/1999	Beecham
	5,883,370	03/16/1999	Walker et al.
	5,885,245	03/23/1999	Lynch et al.
	5,891,035	04/06/1999	Wood et al.